中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (10): 1889-1892.doi: 10.3969/j.issn.1673-8225.2011.10.040

• 干细胞临床实践 clinical practice of stem cells • 上一篇    下一篇

自体分选造血干细胞和异体脐带间充质干细胞移植治疗神经系统变性疾病

王黎明1，周建军1，白  雯1，白  槟1，李建军1，王立华2，刘拥军2   

  1. 1解放军第323医院细胞治疗中心，陕西省西安市 710054
    2中国医学科学院血液学研究所血液学国家重点实验室，天津市 300020
  • 收稿日期:2010-10-08 修回日期:2010-11-12 出版日期:2011-03-05 发布日期:2011-03-05
  • 通讯作者: 刘拥军，中国医学科学院血液学研究所血液学国家重点实验室，天津市 300020 andyliuliu2001@yahoo.com.cn
  • 作者简介:王黎明★，女，1954年生，1994年解放军第四军医大学毕业，硕士，主任医师，主要从事血液、风湿免疫病，及干细胞临床应用的研究。wanglm@fmmu.edu.cn

Autologous hematopoietic stem cell transplantation and allogeneic umbilical cord mesenchymal stem cell transplantation in the treatment of neural degenerative diseases

Wang Li-ming1, Zhou Jian-jun1, Bai Wen1, Bai Bing1, Li Jian-jun1, Wang Li-hua2, Liu Yong-jun2   

  1. 1Cell Therapy Center, The 323 Hospital of Chinese PLA, Xi’an   710054, Shaanxi Province, China
    2National State Key Laboratory of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin   300020, China
  • Received:2010-10-08 Revised:2010-11-12 Online:2011-03-05 Published:2011-03-05
  • Contact: Liu Yong-jun, National State Key Laboratory of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin 300020, China andyliuliu2001@ yahoo.com.cn
  • About author:Wang Li-ming★, Master, Chief physician, Cell Therapy Center, The 323 Hospital of Chinese PLA, Xi’an 710054, Shaanxi Province, China wanglm@fmmu.edu.cn

PDF

621

被引次数

7

摘要：

背景：将自体分选造血干细胞和异体脐带间充质干细胞技术应用于临床，试图寻找一种新的治疗神经系统变性疾病的可行方法。
目的：探讨自体分选CD34+造血干细胞和异体脐带间充质干细胞治疗神经系统变性病的可行性。
方法：入选神经系统变性病患者21例，其中运动神经元病15例，脊髓小脑共济失调6例。取4 mL的脐带间充质干细胞或自体分选干细胞液经腰穿注射到患者蛛网膜下腔，每次注射的细胞数1.0×107。于干细胞治疗后3个月进行评分。
结果与结论：15例运动神经元病患者，治疗总有效率为80%，治疗前后的脊髓侧索硬化功能分级量表和自我评估问卷评分差异有显著性意义(P < 0.05)；6例脊髓小脑共济失调患者，按ICARS评分，4例病情等级下降，治疗总有效率为77%。21例中4例有轻度低颅压性头痛(腰穿后)，14例采用脐带间充质干细胞治疗的患者中2例在治疗后2 h出现短暂发热，其余患者治疗后未见明显不良反应。结果初步表明自体分选造血干细胞和异体脐带间充质干细胞治疗神经系统变性病临床疗效肯定，安全可行。

关键词: 造血干细胞, 脐带间充质干细胞, 神经系统变性病, 运动神经元病, 脊髓小脑共济失调

Abstract:

BACKGROUND: Autologous hematopoietic stem cell transplantation (AHSCT) and allogeneic umbilical cord mesenchymal stem cell (UC-MSC) technology are applied in clinic, trying to find a new feasible method of the treatment of neural degenerative disease.
OBJECTIVE: To study the feasibility of AHSCT CD34+ and UC-MSC in the treatment of neural degenerative disease.
METHODS: A total of 21 patients with neural degenerative disease were selected, including 15 cases with motor neuron disease (MND), 6 cases with spinocerebellar ataxia. A volume of 4 mL UC-MSC or AHSCT solution was injected into subarachnoid space through lumbar puncture; the number of injected cells was 1.0×107 each time. At 3 months following stem cells therapy, all patients were scored.
RESULTS AND CONCLUSION: In 15 patients with MND, the total effective rate was 80%. There were significant differences between the acute lateral sclerosis (ALS) functional rating scale and the self-assessment questionnaire scores before and after treatment (P < 0.05). Six cases with spinal cerebellar ataxia underwent international cooperative ataxiarating scale (ICARS). The grade of disease condition was reduced in 4 cases; the total effective rate was 77%. Four of the 21 cases had mild intracranial hypotension headache (after lumbar puncture). Two of the 14 patients with the treatment of UC-MSC had transient fever at 2 hours after treatment. The remaining patients had no significant adverse reactions after treatment. The results primarily demonstrated that the AHSCT and UC-MSC have a positive clinical effect, which are safe and feasible in the treatment of neural degenerative disease.

中图分类号: